Swintenel read
Fundamentals-led
ABBV: +29.2% over the past year. AbbVie Inc. is a biopharmaceutical company that develops and sells medicines and therapies.
→ swintenel analyze ABBV
Healthcare · Drug Manufacturers - General
Swintenel read
Fundamentals-led
ABBV: +29.2% over the past year. AbbVie Inc. is a biopharmaceutical company that develops and sells medicines and therapies.
Growth beats expectations and the speculation premium holds — upside if narrative strengthens.
Expectations reset lower — miss risk is elevated with 0% speculation premium priced in.
Price series and mix come from the ticker cache. Quote multiples and annual statements come from FMP when the key is configured. Headlines and earnings dates come from the scan cache. Missing fields stay as dashes — we do not invent a live tape or a buy/sell rating.
Price mix
We split the last price into three parts: what looks backed by earnings today, what already assumes growth, and what is still a bet. This describes the price. It is not a rating.
How much of today's price looks backed by what the company already earns. Not a guess about next year.
How much of the price already assumes growth that looks more like it is on the books, sitting on top of today's earnings.
What is left after those two. The market is paying for a future that still has to show up. That leftover can stay, shrink, or reverse. It is not a score or a buy signal.
Constructive and risk cases sit on Overview. What would break the thesis lives in Thesis check.
When they report
Two things: when you'd hear the next report, and whether profit per share has been going up.
Next report on file is Wed, Feb 3, 2027 · in 92 days. That's when you'd hear the latest numbers.
Last print
Next print
Wed, Feb 3, 2027 · in 92 days
Profit per share is roughly flat versus a year ago.
Options in the cache imply about a 5.1% swing either way. Not a call on up or down.
Sales
Sales
Wed, Feb 3, 2027 · in 92 days
Headlines
Operational memo
What has to stay true, and what would break it. A price drop alone does not count. Street counts stay in the rail; definitions are at the bottom of this page.
The memo bet on AbbVie: AbbVie Inc. It sits in Drug Manufacturers - General.
Full description, quality metrics, and statements live under Depth. This tab is the economics the memo is betting on — and whether the latest facts still match that bet.
When the economics of AbbVie changed — or looked like they might — here is what that looks like now.
Recent headlines in the cache: "Three Stocks That May Be Trading Below Their Estimated Value In May 2026"; "Two Paths to Growth: Johnson & Johnson vs AbbVie". Treat these as starting points to verify against filings and calls — not as settled proof.
The next dated print on the calendar is 2027-02-03. The working memo line is: AbbVie Inc. is a biopharmaceutical company that develops and sells medicines and therapies.
A price move alone does not confirm or break that line.
To judge whether that matters, you need how the company got here.
Over the cached window from 2025-10-30 to 2026-10-30, the stock path is +29.2%. That move is the run-up (or drawdown) the current price contains — not a verdict.
Reported revenue growth in the fundamentals pack is 8.60% year over year. Digest earnings note: $1.8B | Net Margin: 3.0%.
Separate what reported numbers have already shown from what is still promised. Must-stay-true checks are in the memo below — not restated here.
A large move should make you careful - the relevant history explains why people disagree.
The price history in this cache shows 0 drawdowns of 30% or more across about 1.1 years. That is a base rate, not a forecast.
The standing bear case on this page: Expectations reset lower — miss risk is elevated with 0% speculation premium priced in. The countercase: Growth beats expectations and the speculation premium holds — upside if narrative strengthens.
The memo below is what must stay true for ABBV, and what would prove it wrong.
The ABBV memo turns on what must stay true, and what would prove it wrong.
AbbVie Inc. is a biopharmaceutical company that develops and sells medicines and therapies. The company has shown solid business quality with revenue growing 8.6% year-over-year, reaching $61.2 billion. However, its net income margin is only 3.0%, and ROE is a negative 55.54%. AbbVie looks reasonably valued, with a forward P/E of 13.67 and a P/S ratio of 6.26, while analysts have a consensus target price of $253.85. …
Below we track the key markers for this stock. If any of them break, that is a mechanical hit to the thesis. A stock drop alone does not count.
Must be true Price implies ~0%/yr revenue growth, in line with ~2%/yr history.
UncheckedBreaks if: Evidence arrives that directly contradicts: “Price implies ~0%/yr revenue growth, in line with ~2%/yr history.”
Where we look: Not scheduled yet — checkpoint lands when the engine drafts one.
Analyst price targets
Consensus $294 · median $300
Range $235 – $325 · -0.3% vs last
via FMP · as of Nov 3, 2026
Street grade mix
0 strong buy · 31 buy · 12 hold · 1 sell · 0 strong sell
44 ratings · FMP label “Buy” — counts only, not a recommendation.
via FMP · as of Nov 3, 2026
Street annual estimates
FY 2026 · revenue $67.61B · EPS $13.92
What analysts publish for the next annual period (15 EPS estimates) — not a Swintenel forecast.
via FMP · as of Nov 3, 2026
RSI
RSI(14) = 72.8 · bar 2026-10-30
RSI (Relative Strength Index) measures recent price momentum on a 0–100 scale. Readings under 30 are often called 'oversold'; over 70 'overbought' — labels for the reading, not trade advice.
via FMP · as of Nov 3, 2026
Insider Form 4 activity
Y2026 Q3: 3 acquire / 2 dispose transactions
Descriptive ownership activity from filings — not a buy/sell signal.
via FMP · as of Nov 3, 2026
Average close
50-day avg $269.29 · 200-day avg $237.1
Simple moving averages of recent closes — context for where price sits, not a signal.
via FMP · as of Nov 3, 2026
Dossier
Cached research in tabs. More filled dots means higher versus other names. Not a rating.
AbbVie Inc. · Healthcare · Drug Manufacturers - General
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozur
Reported quality from statements first. More filled dots means higher versus other names. Not a rating.
Ownership, short interest, and Form 4 stats. Named 13F holder tables are not on this FMP tier.
Digest compiled by Swintenel from SEC EDGAR filings and internal agent research. Not investment advice. Third-party data vendors are not affiliated with Swintenel.